Cumberland Pharmaceuticals Awards Oracle CRM Implementation to SFCG

Austin, TX – March 7^th 2012 – Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, has awarded the implementation of their next generation CRM to SFCG, a leader in sales, marketing and service solutions for life sciences companies.

SFCG, a leader in Oracle CRM solutions for life sciences companies and mobility solutions, will implement Oracle CRM On Demand with Oracle Disconnected Sales For Tablets. The comprehensive solution will be available both in and out of the cloud.  “While cloud computing is nearly pervasive, our sales people need to be productive wherever they go and in any situation.  Oracle’s solution allows that to happen and SFCG has the expertise to ensure the entire solution meets our business needs,” affirms Cumberland CFO, Rick S. Green.

“We’re very excited to welcome Cumberland to the SFCG portfolio of Life Science clients,” states SFCG President and CEO, David Ewing.  “With the ever increasing array of pharmaceutical solutions, today’s pharmaceutical sales force needs to focus on the twin fundamentals of effectiveness and efficiency more than ever. Having mobile, iPad-based solutions is part of an overall array of enabling technologies that will help Cumberland build operational excellence, compliance and long term competitive advantage.”

About SFCG:  SFCG is a sales, marketing and service company founded in 2001 by President and CEO, David Ewing. SFCG has been an Oracle Gold Specialized Partner since 2005 and is a leading Oracle partner for CRM On Demand.   SFCG has helped over 250 clients drive revenue, increase productivity and understand how to turn the latest business technology into tangible business results. For more information, please visit the company’s website at www.sfcg.com.

About Cumberland Pharmaceuticals: Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information, please visit the Company's website at www.cumberlandpharma.com.

Contact:

Tiffany Stavinoha
260 Addie Roy, STE 110
Austin, TX 78746
512-243-7340 x 515
###